Ambrx Biopharma Inc. [Rocket]

Overview

Ambrx Biopharma Inc.

Add to portfolio

Recent News + Filings (All items)

Date Filed	Type	Description
10/12/2023	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/12/2023	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/12/2023	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/12/2023	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/12/2023	25-NSE	Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
10/12/2023	8-K	Quarterly results
10/10/2023	8-K	Quarterly results

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19
Revenues	7.5	13.7	10.3
Revenue growth	-45.5%	32.6%
Cost of goods sold	0.0	0.0	0.0
Gross profit	7.5	13.7	10.3
Gross margin	100.0%	100.0%	100.0%
Research and development	54.8	20.4	26.4
General and administrative	17.1	6.4	6.4
EBITA	-62.8	-11.7	-21.0
EBITA margin	-842.7%	-85.3%	-203.9%
Amortization of intangibles	1.6	1.5	1.5
EBIT	-64.4	-13.1	-22.5
EBIT margin	-864.2%	-95.9%	-217.9%
Pre-tax income	-68.3	-17.8	-22.3
Income taxes	0.0	0.0	0.0
Tax rate			0.0%
Net income	-68.3	-17.8	-22.3
Net margin	-916.0%	-130.5%	-216.4%

Diluted EPS	($0.48)	($0.15)	($0.16)
Shares outstanding (diluted)	143.2	115.7	136.1

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.